Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation Meeting Abstract
| Authors: | Goetz, M. P.; Wander, S. A.; Bachelot, T.; Batist, G.; Cortes, J.; Cristofanilli, M.; Curigliano, G.; De Nonneville, A.; Gal-Yam, E. N.; Jhaveri, K. L.; Ma, C. X.; Parsons, H. A.; Rugo, H. S.; Sammons, S. L.; Stover, D. G.; Twelves, C.; Bardia, A.; Plourde, P. V.; Portman, D. J.; Damodaran, S. |
| Abstract Title: | Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406032 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS1127 |
| Notes: | Meeting Abstract: TPS1127 -- Source: Wos |
